An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 109 (2-3) , 101-108
- https://doi.org/10.1016/s0049-3848(03)00099-9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Antithrombotic Therapy in ChildrenChest, 2001
- Outcome of Pediatric Thromboembolic Disease: A Report from the Canadian Childhood Thrombophilia RegistryPediatric Research, 2000
- Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of Venous Thromboembolic ComplicationsThe Journal of Pediatrics, 1998
- Benefit of Heparin in Central Venous and Pulmonary Artery CathetersChest, 1998
- Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgeryArchives of internal medicine (1960), 1996
- Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding studyThe Journal of Pediatrics, 1996
- Low-Molecular-Weight Heparinoid Orgaran Is More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip FractureCirculation, 1996
- Venous thromboembolic complications in childrenThe Journal of Pediatrics, 1993
- Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous CathetersAnnals of Internal Medicine, 1990
- Arachidonic Acid-Induced Aggregation of Platelets from Human Cord Blood Compared with Platelets from AdultsNeonatology, 1985